Patents by Inventor Lichao FANG

Lichao FANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF FPR1 AND METHODS OF USING THE SAME
    Publication number: 20240018124
    Abstract: Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
    Type: Application
    Filed: March 17, 2022
    Publication date: January 18, 2024
    Inventors: Tianwei MA, Feng SHI, Lichao FANG, Zheng HUANG, Hua Viola LIN, Yue XIAO
  • Cathepsin L inhibitors
    Patent number: 11858905
    Abstract: The present disclosure provides a plurality of the compounds. The compounds are capable of inhibiting Cathepsin L (CatL). A composition including at least one of these compounds is also provided. A method for treating or preventing one or more CatL-related diseases in a subject is further provided. The method may include administering the composition to the subject.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: January 2, 2024
    Assignees: BIOFRONT THERAPEUTICS (BEIJING) CO., LTD., RK PHARMTECH (BEIJING) LTD.
    Inventors: Lichao Fang, Yayi Wang, Tianwei Ma, Ling Song, Zheng Huang, Jin-Kui Yang, Shuo Gu
  • SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES
    Publication number: 20230142285
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.
    Type: Application
    Filed: December 17, 2020
    Publication date: May 11, 2023
    Inventors: Wei CAI, Xuedong DAI, Oliver Alexis Georges QUEROLLE, Johannes Wilhelmus John F. THURING, Yingtao LIU, Lianzhu LIU, Yanping XU, Liqiang FU, Ming LI, Lichao FANG, Xianguin DENG, Qiwu ZHAO, Kangying LI, Alicia Tee Fuay NG, Nicolas Freddy J. DARVILLE, Edward CLEATOR, Gregor Thomas URBANIETZ, William Marc MATON, Vineet PANDA
  • HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS
    Publication number: 20220289732
    Abstract: The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.
    Type: Application
    Filed: August 7, 2020
    Publication date: September 15, 2022
    Inventors: Lichao FANG, Zhenting GAO, Xiangqing JIANG, Kevin Kun Chin LIU, Sing Yeung Frankie MAK, Counde OYANG, Ce WANG, Tao WANG, Jianping WU, Wu YINGMING, Qitao XIAO